Nalaganje...

Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes

BACKGROUND: Based on a single placebo-controlled randomized clinical trial, empagliflozin is licensed to reduce cardiovascular death in diabetes and comorbid cardiovascular disease. METHODS: We examined the comparative effectiveness of empagliflozin on mortality and cardiovascular morbidity in type...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Transl Med
Main Authors: Aronow, Wilbert S., Shamliyan, Tatyana A.
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2017
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5733315/
https://ncbi.nlm.nih.gov/pubmed/29285488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2017.08.43
Oznake: Označite
Brez oznak, prvi označite!